Clinical trial NCT06062836: The Platform for Interdisciplinary Cardiovascular-metabolic-neurovascular Diseases (PICMAN)
Official title: The Platform for Interdisciplinary Cardiovascular-metabolic-neurovascular Diseases (PICMAN) Across National University Health System (NUHS)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cardiometabolic Syndrome
Lead sponsor: National University Hospital, Singapore
Sponsor class: OTHER
First posted: 2023-10-02
Enrollment: 120
Sex: ALL
Minimum age (years): 21
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants between the ages of 21 and 70 at screening without a prior history of MACE, coronary artery disease diagnosis, established diabetes, with a calculated 10-year ASCVD risk \> 5% based on QRISK3 calculator are eligible for PICMAN. Recruitment of individuals takes place at NUHS, where community-dwelling individuals without cardiac disease will be referred via outreach to primary care and community partners in Singapore.

Brief summary: Background Changes in metabolism and mitochondrial function appear to precede cardiac dysfunction, with much evidence supporting metabolic dysregulation as one of the earliest precursors of cardiovascular disease. We hypothesise that quantifiable metabolic inflexibility may be representative of an individual in his/her silent, but high-risk progression towards insulin resistance, diabetes and cardiovascular disease. The platform for interdisciplinary cardiovascular-metabolic-neurovascular diseases (PICMAN) across National University Health System (NUHS) is a pilot, prospective, multi-ethnic cohort study in Singapore.

Through extensive phenotyping in a preventive cardiology cohort, the central aim is to define the metabolic flexibility range in a cohort of individuals at elevated risk of atherosclerotic cardiovascular disease, to correlate metabolic flexibility to measures of cardiometabolic health, including diastolic dysfunction, coronary and cerebral atherosclerosis, body fat distribution and severity of non-alcoholic fatty liver disease.

Detailed description: Aims

1. Define norms for metabolic flexibility in a multi-ethnic Southeast Asian cohort of individuals without manifest ASCVD
2. Understand the association of metabolic inflexibility with cardiovascular measures of diastolic dysfunction and coronary and cerebral atherosclerosis
3. Understand the association of metabolic inflexibility with measures of body fat distribution
4. Understand the correlation between metabolic flexibility and insulin sensitivity along the spectrum of subclinical cardiovascular disease and severity of non-alcoholic fatty liver disease
5. Associations of the gut microbiome as well as metabolomic and molecular markers with cardio-cerebrovascular measures, metabolic flexibility and liver fibrosis

The PICMAN study seeks to lay the foundations for further future larger scale and more experimentally ambitious studies based on the overarching hypothesis that metabolic flexibility is an early marker in subclinical cardiovascular disease, indicating a point of timely intervention where the disease process is still reversible. The importance of a deeply-phenotyped local cohort will allow us to study the progression of CVD in seemingly well adults, converging imaging, biochemical, metabolic markers, and 'omics analysis.

Eligibility criteria: Inclusion Criteria:

* Patients aged 21-70 at screening
* 10-year ASCVD risk \> 5% measured by QRISK 3 calculator

Exclusion Criteria:

* Established DM (Prior diagnosis, long term medications or HbA1c \>=6.5)
* Established CVD, such as ischemic heart disease, cerebrovascular accident, heart failure, atrial fibrillation
* Pregnancy
* Known contraindications to CT scan, such as allergy to contrast

Primary outcomes:
measure: Metabolic flexibility
timeFrame: Up to 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: National University Health System
Study officials:
affiliation: National University Health System
name: Mayank Dalakoti
role: PRINCIPAL_INVESTIGATOR
affiliation: National University Health System
name: Roger Foo
role: PRINCIPAL_INVESTIGATOR
References: